CMG-SDIC Capital, a private equity firm, and Tigermed, a provider of innovative clinical research solutions, led a $100m Series D funding round in Adlai Nortye, a developer and producer of biotechnology products. The round had participation from investors Wuxi Biologics, Legend Star, Matrix Partners China, Alwin Capital, and Yuanming Capital and DT Capital. Following the latest investment, Adlai Nortye plans to facilitate the clinical trials of pipeline candidates, roll out new drug research programmes, and extend pipelines and talents.